Failure of Pain Control Using Transdermal Fentanyl During Rifampicin Treatment

Journal of Pain and Symptom Management

Volumn 33, Issue 1, 2007, Pages 5-6

  Morii, Hiroaki ^a   Chiba, Mikio ^a   Konishi, Hiroki ^a   Endo, Yoshihiro ^a   Yamaji, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ETHAMBUTOL; FENTANYL; FLURBIPROFEN AXETIL; ISONIAZID; LOXOPROFEN; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; RIFAMPICIN;

ADULT; CANCER PAIN; CASE REPORT; CONSCIOUSNESS DISORDER; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SUBSTITUTION; HUMAN; LETTER; LUNG TUBERCULOSIS; MALE; TREATMENT FAILURE;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; ANTIBIOTICS, ANTITUBERCULAR; DRUG INTERACTIONS; FENTANYL; HUMANS; MALE; MIDDLE AGED; PAIN; RIFAMPIN; TREATMENT FAILURE;

EID: 33845731681     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2006.08.005     Document Type: Letter

References (5)

1. Takane H., Nosaka A., Wakushima H., Hosokawa K., and Ieiri I. Rifampin reduces the analgesic effect of transdermal fentanyl. Ann Pharmacother 39 (2005) 2139-2140
2. Donner B., Zenz M., Tryba M., and Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64 (1996) 527-534
3. Labroo R.B., Paine M.F., Thummel K.E., and Kharasch E.D. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 25 (1997) 1072-1080
4. Kharasch E.D., Whittington D., and Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology 101 (2004) 729-737
5. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245